Logo image of VIR

VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

USA - NASDAQ:VIR - US92764N1028 - Common Stock

6.12 USD
-0.15 (-2.39%)
Last: 10/22/2025, 8:07:26 PM
6.12 USD
0 (0%)
After Hours: 10/22/2025, 8:07:26 PM
Fundamental Rating

3

Overall VIR gets a fundamental rating of 3 out of 10. We evaluated VIR against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VIR as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, VIR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

VIR had negative earnings in the past year.
VIR had a negative operating cash flow in the past year.
In multiple years VIR reported negative net income over the last 5 years.
VIR had negative operating cash flow in 4 of the past 5 years.
VIR Yearly Net Income VS EBIT VS OCF VS FCFVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

1.2 Ratios

VIR has a Return On Assets of -46.14%. This is comparable to the rest of the industry: VIR outperforms 53.56% of its industry peers.
VIR has a Return On Equity of -58.07%. This is in the better half of the industry: VIR outperforms 62.55% of its industry peers.
Industry RankSector Rank
ROA -46.14%
ROE -58.07%
ROIC N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
VIR Yearly ROA, ROE, ROICVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

VIR has a Gross Margin of 96.08%. This is amongst the best in the industry. VIR outperforms 95.13% of its industry peers.
In the last couple of years the Gross Margin of VIR has grown nicely.
VIR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
VIR Yearly Profit, Operating, Gross MarginsVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIR has more shares outstanding than it did 1 year ago.
VIR has more shares outstanding than it did 5 years ago.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VIR Yearly Shares OutstandingVIR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VIR Yearly Total Debt VS Total AssetsVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

VIR has an Altman-Z score of -0.09. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.
VIR has a Altman-Z score of -0.09. This is comparable to the rest of the industry: VIR outperforms 58.43% of its industry peers.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.09
ROIC/WACCN/A
WACC9.32%
VIR Yearly LT Debt VS Equity VS FCFVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B 2B

2.3 Liquidity

VIR has a Current Ratio of 7.01. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VIR (7.01) is better than 69.29% of its industry peers.
A Quick Ratio of 7.01 indicates that VIR has no problem at all paying its short term obligations.
VIR has a better Quick ratio (7.01) than 69.66% of its industry peers.
Industry RankSector Rank
Current Ratio 7.01
Quick Ratio 7.01
VIR Yearly Current Assets VS Current LiabilitesVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for VIR have decreased strongly by -11.73% in the last year.
The Revenue for VIR has decreased by -75.90% in the past year. This is quite bad
VIR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.74% yearly.
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.57%
Revenue 1Y (TTM)-75.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-60.52%

3.2 Future

VIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.23% yearly.
VIR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.82% yearly.
EPS Next Y13.12%
EPS Next 2Y11.82%
EPS Next 3Y10.45%
EPS Next 5Y10.23%
Revenue Next Year-83.95%
Revenue Next 2Y-56.99%
Revenue Next 3Y-35.89%
Revenue Next 5Y3.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIR Price Earnings VS Forward Price EarningsVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIR Per share dataVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.82%
EPS Next 3Y10.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VIR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (10/22/2025, 8:07:26 PM)

After market: 6.12 0 (0%)

6.12

-0.15 (-2.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-24 2025-07-24/bmo
Earnings (Next)10-30 2025-10-30/amc
Inst Owners67.6%
Inst Owner Change-0.04%
Ins Owners1.12%
Ins Owner Change-0.33%
Market Cap850.19M
Revenue(TTM)19.00M
Net Income(TTM)-550229000
Analysts82.86
Price Target17.57 (187.09%)
Short Float %11.26%
Short Ratio9.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.87%
Min EPS beat(2)-9.48%
Max EPS beat(2)-4.26%
EPS beat(4)1
Avg EPS beat(4)-11.67%
Min EPS beat(4)-46.72%
Max EPS beat(4)13.76%
EPS beat(8)3
Avg EPS beat(8)1.33%
EPS beat(12)4
Avg EPS beat(12)48.76%
EPS beat(16)7
Avg EPS beat(16)213.56%
Revenue beat(2)0
Avg Revenue beat(2)-60.45%
Min Revenue beat(2)-65.06%
Max Revenue beat(2)-55.84%
Revenue beat(4)1
Avg Revenue beat(4)-31.9%
Min Revenue beat(4)-65.06%
Max Revenue beat(4)50.52%
Revenue beat(8)3
Avg Revenue beat(8)18.98%
Revenue beat(12)5
Avg Revenue beat(12)13.12%
Revenue beat(16)7
Avg Revenue beat(16)5.49%
PT rev (1m)0%
PT rev (3m)-2.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.09%
EPS NY rev (1m)0.36%
EPS NY rev (3m)-6.19%
Revenue NQ rev (1m)-6.09%
Revenue NQ rev (3m)-25.46%
Revenue NY rev (1m)-4.2%
Revenue NY rev (3m)-37.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 44.75
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-4
EYN/A
EPS(NY)-2.86
Fwd EYN/A
FCF(TTM)-3.36
FCFYN/A
OCF(TTM)-3.29
OCFYN/A
SpS0.14
BVpS6.82
TBVpS6.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -46.14%
ROE -58.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.08%
FCFM N/A
ROA(3y)-16.99%
ROA(5y)-11.28%
ROE(3y)-19.74%
ROE(5y)-12.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.7%
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.21%
Cap/Sales 47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.01
Quick Ratio 7.01
Altman-Z -0.09
F-Score2
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)387.02%
Cap/Depr(5y)331.46%
Cap/Sales(3y)13.03%
Cap/Sales(5y)9.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.57%
EPS Next Y13.12%
EPS Next 2Y11.82%
EPS Next 3Y10.45%
EPS Next 5Y10.23%
Revenue 1Y (TTM)-75.9%
Revenue growth 3Y-59.24%
Revenue growth 5Y55.74%
Sales Q2Q%-60.52%
Revenue Next Year-83.95%
Revenue Next 2Y-56.99%
Revenue Next 3Y-35.89%
Revenue Next 5Y3.82%
EBIT growth 1Y-11.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.71%
EBIT Next 3Y7.47%
EBIT Next 5Y7.12%
FCF growth 1Y-13.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.4%
OCF growth 3YN/A
OCF growth 5YN/A